# V1 Empirics Check — openai/gpt-5.4 (Variant B)

**Model:** openai/gpt-5.4
**Variant:** B
**Date:** 2026-03-30T10:53:54.456807

---

1. **Idea Fidelity**

The paper pursues part of the original manifest, but it also departs from it in important ways.

First, the paper keeps the core proposed design: use ClinicalTrials.gov/AACT-type registry data, compare Phase 2/3 trials to Phase 1 trials, and exploit FDAAA 801 as a transparency mandate in a DiD framework. It also uses a large administrative registry and examines sponsor/geography heterogeneity, which is in the spirit of the manifest.

However, the paper misses two key elements of the original idea. The largest departure is the outcome: the manifest centered on *selective outcome reporting* (outcome switching, positivity of prespecified outcomes, time to posting, etc.), while the paper studies mostly a much coarser outcome, whether any results were ever posted. That is a useful descriptive outcome, but it is not the same contribution. The “primary outcome count” analysis does not really recover selective reporting. Second, the paper does not operationalize actual FDAAA applicability. FDAAA 801 did not simply apply to all Phase 2/3 trials and exempt all Phase 1 trials; applicability depends on whether the trial is an “applicable clinical trial,” including product type, FDA jurisdiction, and other criteria. The manifest recognized some of this nuance; the paper largely abstracts from it. As a result, the treatment definition is substantially noisier than the original idea implied.

So the paper captures the broad policy question, but only partially delivers on the original identification strategy and substantially changes the research question from selective outcome reporting to overall registry reporting.

2. **Summary**

This paper studies whether FDAAA 801 increased reporting of clinical trial results on ClinicalTrials.gov by comparing Phase 2/3 trials to exempt Phase 1 trials before and after 2007. Using the registry universe, it finds a positive pooled DiD estimate, especially for industry-sponsored and US-site trials, but it also documents clear pre-trends that weaken the central causal claim.

The topic is important, the data source is promising, and the paper is refreshingly candid that the pooled estimate is not cleanly causal. At present, though, the paper does not yet provide a convincing causal estimate of the mandate’s effect, mainly because treatment assignment is too crude and the control group is not persuasive.

3. **Essential Points**

**1. The identification strategy, as implemented, is not credible enough for a causal claim.**  
The paper’s own placebo test shows a strong pre-trend, and the substantive reason is obvious: Phase 1 and Phase 2/3 trials are structurally different products with different scientific, commercial, and publication incentives. Once the paper demonstrates nonparallel pre-trends, the baseline DiD should no longer be presented as the main estimate of a mandate effect. To be viable, the paper needs either (i) a much more convincing control group, or (ii) a design that compares actually covered vs. non-covered trials within more comparable strata. At minimum, the paper should narrow the comparison set sharply (e.g., within sponsor type, product category, US involvement, therapeutic area, and perhaps phase-specific analyses rather than pooled Phase 2/3).

**2. The treatment is mismeasured: FDAAA applicability is not equivalent to “Phase 2/3.”**  
This is more than a nuance. FDAAA 801 applies to “applicable clinical trials,” not all Phase 2/3 studies in the registry. Many non-US or non-FDA-regulated trials in the treated group were not legally covered, while some classification choices (e.g., Early Phase 1, device studies, foreign-only trials) matter directly for coverage. This attenuation/noise also complicates interpretation of the heterogeneous results. The paper needs a much more careful covered-trial definition, ideally using ACT proxies developed in the ClinicalTrials.gov/AACT community, and should clearly distinguish intent-to-treat by phase from treatment-on-the-treated among likely covered studies.

**3. The paper’s current outcomes do not support the claimed contribution about selective reporting or the “market for scientific evidence.”**  
An indicator for whether results were ever posted is meaningful, but it is not evidence on selective outcome reporting in the stronger sense emphasized in the introduction and manifest. The “number of primary outcomes” is also a weak proxy and hard to interpret. If the contribution is about transparency and selective reporting, the paper needs outcomes closer to that concept: timeliness relative to legal deadlines, consistency between registered and reported primary outcomes, missingness of primary outcome data, or at least a more precise compliance measure tied to completion date. Otherwise the paper should scale back its claims and present itself as a study of registry results posting, not selective reporting broadly.

4. **Suggestions**

The paper has the ingredients for a useful short paper, but it needs to be reframed and tightened around what the data can actually identify.

First, I strongly encourage the authors to rebuild the sample around **likely ACT status** rather than phase alone. ClinicalTrials.gov and AACT users often construct “probable applicable clinical trial” indicators using study type, intervention type, FDA-regulated drug/device fields, phase, US locations, IND/IDE proxies, and status. Even if these fields are incomplete in earlier years, a transparent approximation would be far superior to the current phase-based treatment definition. A clean version of the paper could become: among trials likely subject to FDAAA, did results posting increase relative to observably similar but likely exempt trials? That is a narrower but much stronger contribution.

Second, the paper should reconsider the **timing of treatment and outcome measurement**. FDAAA’s results reporting requirement is tied to the *primary completion date*, not start date. The current design assigns treatment by start year and then asks whether a trial has ever posted results by the 2026 extraction date. That introduces a lot of heterogeneity in exposure and compliance windows. A better design would define cohorts by primary completion year and examine whether results were posted within 12 months, 24 months, etc. This would align the outcome with the statute and avoid conflating slow eventual posting with legal compliance. A survival/hazard specification for time-to-results-posting could be especially informative and would hew more closely to the manifest.

Third, I would substantially tone down the causal language around the **heterogeneity results**. The industry/non-industry and US/non-US splits are interesting, and they are probably the most suggestive patterns in the paper. But the claim that the industry effect “cannot be explained by differential pre-trends alone” is too strong without showing subgroup-specific event studies and pre-trend tests. The natural next step is to present those figures. If pre-trends are flatter within industry or within US-site studies, that would materially strengthen the argument. If not, the mechanism story must be softened.

Relatedly, I would like to see **event-study graphs** in the main text, not just references to pre-trends through a placebo regression. For a short paper, one clean figure showing annual treatment-control gaps for the main sample and perhaps one key subgroup would add a lot. Right now the reader has to infer the dynamics from a single placebo coefficient.

Fourth, the paper should address **sample selection into the registry** much more carefully. The analysis conditions on being in ClinicalTrials.gov, but FDAAA also affected incentives to register. If coverage expanded differentially after 2007, the composition of observed treated trials could change even if behavior conditional on being observed did not. The paper gestures at this concern but does not really test it. Useful diagnostics would include trends in counts of trials by phase/sponsor/US site, changes in observables, and perhaps restricting to sponsors active both before and after 2007. Sponsor fixed effects or sponsor-by-phase balanced panels, if feasible, would help.

Fifth, I recommend a sharper distinction between **results posting on ClinicalTrials.gov** and **publication/disclosure more generally**. The introduction motivates file-drawer problems in journal publication, but the measured outcome is registry posting. That is still important, but conceptually narrower. The paper will read as more coherent if it defines its contribution as estimating the effect of disclosure mandates on *registry-based results disclosure*, rather than on the whole market for scientific evidence.

Sixth, the “primary outcome count” mechanism is currently underdeveloped and may distract from the stronger parts of the paper. It is not obvious that fewer listed primary outcomes reflect “discipline” rather than form changes, coding changes, or compositional shifts. Unless the authors can validate this measure and show stable registry definitions over time, I would either move it to an appendix or replace it with a more direct registry-compliance outcome: presence of a primary outcome description, presence of a completion date, or concordance between registered and reported outcomes if those links can be built from AACT tables.

Seventh, the paper would benefit from more institutional precision. For example:
- distinguish clearly between registration requirements and results-reporting requirements;
- clarify that not all covered trials are drug efficacy trials;
- explain the role of the 2016/2017 Final Rule and why the sample ends in 2015;
- be precise that foreign trials can still be covered under some conditions, so “non-US” is only a rough proxy for lower enforceability.

Eighth, inference should be handled more carefully given the **small number of time clusters**. The paper says wild bootstrap robustness was verified, but those results are not shown. They should be reported, at least for the main coefficient and key subgroup estimates. With 13 year clusters, this matters.

Ninth, there is room for a more compelling **AER: Insights-style contribution** if the authors simplify. One possibility is:
- focus only on likely ACT trials;
- use completion-date cohorts;
- outcome = posted within statutory window;
- show a main event study plus one heterogeneity split (industry vs non-industry);
- frame the paper as evidence that mandates increase disclosure only where enforcement is credible.

That would be cleaner than trying to span publication bias, selective outcome reporting, pre-specification, and broad lessons for economics pre-registration all at once.

Finally, I encourage the authors to preserve the paper’s admirable honesty. The current draft is strongest when it admits the pooled DiD is compromised. If the paper is revised around that insight—by tightening treatment definition, aligning timing with the law, and scaling claims to what is truly identified—it could become a useful paper on transparency regulation. In its current form, though, the evidence is better described as suggestive than causal.
